CG
ZNTL icon

Cutler Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Cutler Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$9K Sell
600
-300
-33% -$4.13K ﹤0.01% 1353
2023
Q4 		$13K Hold
900
– – ﹤0.01% 2265
2023
Q3 		$18K Buy
+900
New +$22.8K ﹤0.01% 2126
2021
Q4 		– Sell
-9,050
Closed -$603K – 6237
2021
Q3 		$603K Buy
+9,050
New +$522K 0.03% 691

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Cutler Group's ZNTL Position: Q1 2024 in Review

Cutler Group reduced its Zentalis Pharmaceuticals (ZNTL) stake by 33% in Q1 2024, selling an estimated $4.13K and leaving 600 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1353.

Cutler Group first reported a position in ZNTL in Q3 2021 and has held it in 4 quarters since. The position peaked at $603K in Q3 2021. 142 funds tracked by Wall St. Rank hold ZNTL as of Q1 2024.

  • Cutler Group held 600 shares of Zentalis Pharmaceuticals worth $9K as of Q1 2024.
  • Cutler Group sold 300 Zentalis Pharmaceuticals shares in Q1 2024, an estimated $4.13K.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1353 holding.
  • Cutler Group first reported a position in Zentalis Pharmaceuticals in Q3 2021 and has held it in 4 quarters since.
  • Cutler Group's Zentalis Pharmaceuticals position peaked at $603K in Q3 2021.
  • 142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.